Evaluation of Two Dermatophyte qPCR Kits on Skin and Keratinous Samples.
1 other identifier
observational
120
1 country
1
Brief Summary
Superficial fungal infections (onychomycosis, dermatophytosis, tinea, etc.) caused by dermatophytes are common in the general population, affecting 20-25% worldwide (1, 2). In our practice, the most frequently observed clinical presentation is onychomycosis, with a prevalence ranging from 2% to 16.7% (3). However, diagnosing this fungal infection is challenging due to its lack of specificity and the long culture turnaround time (up to one month). A molecular approach could overcome these two limitations. Currently, upon sample receipt, a direct mycological examination is performed alongside culture on specific media. If culture is positive, species or genus identification is carried out. Thus, the current reference method is a positive direct examination and/or a positive dermatophyte culture. Over the past four years (2020-2023), 49.85% of samples analyzed in our laboratory were positive (direct exam ± culture). Several PCR kits are available for molecular detection of dermatophytes in skin and keratinous samples, and initial studies report promising performance: sensitivity ranging from 78.5% to 96.5% and specificity from 89.1% to 100%. The study aims to determine the role of molecular diagnostics in these mycodermatological conditions and to compare the performance of two commercial kits. Primary objective: Determine the diagnostic performance of two molecular techniques for detecting dermatophytes. The reference technique (gold standard) will be the presence of dermatophytes established by direct fungal examination. If the direct examination is negative, fungal culture will be performed for confirmation. Secondary objectives: Compare the diagnostic performance of the two molecular biology kits. Compare the average turnaround time for results.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 27, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
November 20, 2025
CompletedFirst Submitted
Initial submission to the registry
November 26, 2025
CompletedFirst Posted
Study publicly available on registry
December 8, 2025
CompletedDecember 9, 2025
December 1, 2025
10 months
November 26, 2025
December 8, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
dermatophytes : yes / no and species involved
1 month
Interventions
multiplex dermatophytes PCR
Eligibility Criteria
Patients consulting at CHRU Nancy for suspected dermatophyte infection.
You may qualify if:
- Patients consulting at CHRU Nancy for suspected dermatophyte infection.
You may not qualify if:
- out CHRU Nancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHRU Nancy
Vandœuvre-lès-Nancy, 54500, France
Biospecimen
Skin, nail, hair
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- PU-PH
Study Record Dates
First Submitted
November 26, 2025
First Posted
December 8, 2025
Study Start
December 27, 2024
Primary Completion
November 1, 2025
Study Completion
November 20, 2025
Last Updated
December 9, 2025
Record last verified: 2025-12